The quality of life of children with attention deficit/ hyperactivity disorder: a systematic review by Danckaerts, Marina et al.
www.ssoar.info
The quality of life of children with attention deficit/
hyperactivity disorder: a systematic review
Danckaerts, Marina; Sonuga-Barke, Edmund J. S.; Banaschewski, Tobias;
Buitelaar, Jan; Döpfner, Manfred; Hollis, Chris; Santosh, Paramala;
Rothenberger, Aribert; Sergeant, Joseph; Steinhausen, Hans-Christoph;
Taylor, Eric; Zuddas, Alessandro; Coghill, David
Postprint / Postprint
Zeitschriftenartikel / journal article
Zur Verfügung gestellt in Kooperation mit / provided in cooperation with:
www.peerproject.eu
Empfohlene Zitierung / Suggested Citation:
Danckaerts, M., Sonuga-Barke, E. J. S., Banaschewski, T., Buitelaar, J., Döpfner, M., Hollis, C., ... Coghill, D. (2009).
The quality of life of children with attention deficit/ hyperactivity disorder: a systematic review. European Child &
Adolescent Psychiatry, 19(2), 83-105. https://doi.org/10.1007/s00787-009-0046-3
Nutzungsbedingungen:
Dieser Text wird unter dem "PEER Licence Agreement zur
Verfügung" gestellt. Nähere Auskünfte zum PEER-Projekt finden
Sie hier: http://www.peerproject.eu Gewährt wird ein nicht
exklusives, nicht übertragbares, persönliches und beschränktes
Recht auf Nutzung dieses Dokuments. Dieses Dokument
ist ausschließlich für den persönlichen, nicht-kommerziellen
Gebrauch bestimmt. Auf sämtlichen Kopien dieses Dokuments
müssen alle Urheberrechtshinweise und sonstigen Hinweise
auf gesetzlichen Schutz beibehalten werden. Sie dürfen dieses
Dokument nicht in irgendeiner Weise abändern, noch dürfen
Sie dieses Dokument für öffentliche oder kommerzielle Zwecke
vervielfältigen, öffentlich ausstellen, aufführen, vertreiben oder
anderweitig nutzen.
Mit der Verwendung dieses Dokuments erkennen Sie die
Nutzungsbedingungen an.
Terms of use:
This document is made available under the "PEER Licence
Agreement ". For more Information regarding the PEER-project
see: http://www.peerproject.eu This document is solely intended
for your personal, non-commercial use.All of the copies of
this documents must retain all copyright information and other
information regarding legal protection. You are not allowed to alter
this document in any way, to copy it for public or commercial
purposes, to exhibit the document in public, to perform, distribute
or otherwise use the document in public.
By using this particular document, you accept the above-stated
conditions of use.
Diese Version ist zitierbar unter / This version is citable under:
https://nbn-resolving.org/urn:nbn:de:0168-ssoar-202937
REVIEW ARTICLE
The quality of life of children with attention deficit/hyperactivity
disorder: a systematic review
Marina Danckaerts Æ Edmund J. S. Sonuga-Barke Æ Tobias Banaschewski Æ Jan Buitelaar Æ
Manfred Do¨pfner Æ Chris Hollis Æ Paramala Santosh Æ Aribert Rothenberger Æ Joseph Sergeant Æ
Hans-Christoph Steinhausen Æ Eric Taylor Æ Alessandro Zuddas Æ David Coghill
Received: 28 October 2008 / Accepted: 8 July 2009 / Published online: 26 July 2009
 Springer-Verlag 2009
Abstract Quality of life (QoL) describes an individual’s
subjective perception of their position in life as evidenced
by their physical, psychological, and social functioning.
QoL has become an increasingly important measure of
outcome in child mental health clinical work and research.
Here we provide a systematic review of QoL studies in
children and young people with attention deficit hyperac-
tivity disorder (ADHD) and address three main questions.
(1) What is the impact of ADHD on QoL? (2) What are the
relationships between ADHD symptoms, functional
impairment and the mediators and moderators of QoL in
ADHD? (3) Does the treatment of ADHD impact on QoL?
Databases were systematically searched to identify
research studies describing QoL in ADHD. Thirty six rel-
evant articles were identified. Robust negative effects on
QoL are reported by the parents of children with ADHD
across a broad range of psycho-social, achievement and
self evaluation domains. Children with ADHD rate their
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own QoL less negatively than their parents and do not
always seeing themselves as functioning less well than
healthy controls. ADHD has a comparable overall impact
on QoL compared to other mental health conditions and
severe physical disorders. Increased symptom level and
impairment predicts poorer QoL. The presence of comor-
bid conditions or psychosocial stressors helps explain these
effects. There is emerging evidence that QoL improves
with effective treatment. In conclusion, ADHD seriously
compromises QoL especially when seen from a parents’
perspective. QoL outcomes should be included as a matter
of course in future treatment studies.
Keywords Attention deficit/hyperactivity disorder
(ADHD)  Quality of life  Systematic review
Introduction
As medicine has moved on from a ‘‘life preserving’’ to a
‘‘health promoting’’ science [95], the concept of Quality
of Life (QoL) has become increasingly important in the
study of medical conditions, their impact and their out-
come [18]. The QoL concept has been defined in many
ways, but all definitions, to a greater or lesser extent,
emphasize the ideal state as one of general well-being in
which an individual’s day-to-day functioning, across a
wide range of domains, is unencumbered by the poten-
tially adverse impact of disease or disorder. Leidy et al.
[44] defined QoL as ‘‘an individual’s subjective percep-
tion of the impact of health status, including disease and
treatment, on physical, psychological, and social func-
tioning.’’ This is compatible with the WHO QoL group’s
description of QoL as ‘‘the individuals perception of their
position in life, in the context of culture and value sys-
tems in which they live, and in relation to their goals,
expectations, standards and concerns’’ [91]. Almost all
QoL definitions and measures include physical, social and
psychological domains (although similar domains are
often labelled differently). A cognitive domain is also
commonly included [24]. Although QoL is influenced by
many proximal (i.e., family, friendship) and distal (socio-
economic and cultural) forces, illness is one of the most
potent influences [24]. In addition to the effects of
physical illness on QoL, there is now substantial evidence
that mental illness has major impact [7, 50, 70].
A comprehensive discussion of the issues relating to the
QoL concept in child and adolescent mental health is
beyond the scope of the current review but can be found in
a recent paper by the authors [18]. However, a number of
key conceptual and measurement are discussed below.
Both the DSM-IV-TR [1] and ICD-10 [96] diagnostic
systems emphasize the importance of there being both
symptoms and impairment before a diagnosis of mental
disorder can be made. However, the distinctions between
symptoms and their associated functional impairments are
often not as clear and one would wish and their relation-
ships with QoL, remain under-specified. For example some
QoL items, designed for patients with physical illness, tap
psychiatric symptoms (e.g. ‘‘how often did your child feel
really sad?’’) or the types of impairment commonly asso-
ciated with psychiatric disorders (e.g. ‘‘how often did he/
she finish all of his/her homework?’’). As a consequence
there is significant potential for overlap between instru-
ments designed to measure QoL and those used to measure
either symptomatology or impairment. It is therefore vital
that, as far as possible, we draw clear distinctions between
symptoms (e.g., low mood or poor concentration) and their
potential effects (i.e., functional impairment and reduced
QoL) and then also between impairment on the one hand
and QoL on the other. Otherwise there is a clear risk that
apparent QoL effects are so closely related to symptoms
and impairment that their association with the disorder will
become a tautology.
Also the concept of ‘‘validity’’ of QoL instruments has
been particularly difficult to define and measure due to the
lack of an agreed and objective gold standard of QoL.
Current approaches suggest the employment of quantitative
(e.g. factor analysis) and qualitative (e.g. patient debriefing
questionnaires and patient panels) techniques. While these
procedures have been increasingly used in the development
of instruments to measure QoL in children and young
people the process has not yet been repeated in different
patient groups. And in particular there has been little work
conducted to demonstrate validity in children with mental
health problems.
Another consideration concerns the usefulness of both
generic and disorder-specific measures of QoL and the
relationships between these two very different types of
measure. Generic measures are designed to be more com-
prehensive in their coverage, but may as a consequence be
less sensitive to treatment-related change. Disorder-specific
measures, or modules, focus in on areas of particular
concern in relation to a specific disorder and may therefore
be more sensitive to treatment effects but do readily not
allow comparison with other disorders.
While it is generally accepted that QoL is a multi-
dimensional concept and that the core domains tap into
physical, psychological, cognitive and social aspects of
functioning it is still the case that different QoL measures
define these domains in different ways and then go on to
divide them up into different sub-domains. As a conse-
quence there is a considerable degree of inter-instrument
non-overlap and we cannot simply assume equal coverage
by different measures or that all generic QoL measures
cover the necessary ground. This often makes it difficult to
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make direct comparisons between studies that have
employed different instruments.
QoL is seen primarily as a patient-reported outcome [48,
79] with a key distinction being between independent
assessment (e.g., he/she cannot concentrate and this stops
him or her functioning at school and I think he/she should
feel bad about this) and the ‘‘subjective’’ appraisal (I cannot
concentrate, this stops me working at school and I feel badly
about this and it impacts generally on how I feel about
myself). In this respect a child’s own report seems essential
to accurately capture their QoL. However, this is compli-
cated by several issues. Young children (e.g., before the age
of 7 or 8 years of age) may lack the understanding, insight
or communication skills to provide valid self ratings [10].
This may be accentuated in the case of; children with
learning disabilities; those for whom mental health condi-
tions impact on their ability to reflect and report upon their
internal state accurately (e.g., depression); or as is often the
case with ADHD, where the child is unable to concentrate
and apply themselves to answering a questionnaire. In these
cases one may have to rely on a proxy rating by a parent or a
carer. As a consequence measures of QoL designed for
child populations usually have both a child and parent
completed versions. Clearly a proxy rating will allow only a
partial sense of the overall impact of the condition on QoL
which may place important constraints on the validity of
studies that do not directly ask the child about their QoL. It
is also important to note that the levels of agreement
between child and other informants are modest [39], espe-
cially with regard to the non-observable aspects of QoL.
Parent/carer ratings may, however, provide an important
alternative perspective to that of the child. However, this
does raise important issues about how information from
different informants is combined or compared.
The developmental aspects of QoL have not been well
studied. It is likely that there will be major age-related
differences in the way individuals value different aspects of
QoL, the ways in which they can express these and the
ways that these two factors interact. It is inevitable that in
selecting an instrument for a particular age group one will
have to trade-off the age specificity of item content with
the benefits of potential comparability across ages [48]. If
one focuses too much on adapting instruments for use by a
specific age group then it is likely to become difficult to
compare or to pool data collected from subjects of different
ages. On the other hand, if an instrument does not cover the
necessary constructs within an age then the validity of that
instrument will inevitably be compromised. Careful pilot-
ing of proposed instruments within the age range to be
studied is therefore essential. There are various ways that
instruments can be tailored to make them more age
appropriate. These include; ensuring that questionnaires are
short and written in simple (age appropriate) language;
changing questionnaires into interviews [36, 63]; attempt-
ing to reduce the influence of the adult over the child’s
responses during face-to-face administration; using picto-
rial response formats such as smiley, neutral and sad faces
[17, 24, 34, 61]; using props and puppets [49]; computer-
administered measures [23, 31]; and ensuring that an
appropriate recall period is selected. Younger children can
have difficulties with the time concepts such as 1 week or
1 month [63].
In addition to these general issues relating to the mea-
surement of QoL in children there are issues which are
more specifically related to mental health problems in
children. Mental health disorders will interact in complex
ways with QoL. Mental health difficulties impact on a
person’s capacity to engage effectively in daily activities
and this can have knock-on consequences for their general
sense of well-being. A reduced sense of well-being can also
impact on mental health by, for example, further lowering
mood. In childhood, the effects of mental health difficulties
on QoL are perhaps most obvious in the more severe or
extreme forms of mental health problem (e.g. autism) or
those that impact directly on an individual’s sense of self
worth (e.g. anxiety and depression). However, there is
growing evidence that the, so called, externalizing disor-
ders such as oppositional defiant disorder and attention
deficit/hyperactivity disorder (ADHD) also substantially
reduce the QoL of children and young people in terms of
their subjective sense of wellbeing and their capacity for
everyday functioning.
The goal of this review is to address the issue of QoL in
ADHD through a systematic review of the published liter-
ature. ADHD is a high prevalence disorder of childhood and
adolescence marked by early onset, persistent and pervasive
patterns of inattention, overactivity and impulsivity. It is
associated with impairment across a range of domains.
More specifically ADHD is associated with educational
under-achievement [94], family-related and peer relation-
ship problems [2, 3, 25] and increased anti-social and
delinquent activity [72]. Long term adverse outcomes
include increased risk of substance abuse [14], reduced
vocational opportunities [5] and increased criminal activity
[73]. ADHD is often comorbid with other disorders such as
oppositional defiant disorder (ODD), conduct disorder
(CD), depression and anxiety [11, 12]. ADHD can be suc-
cessfully managed by a combination of stimulant medica-
tion and psychosocial approaches which reduce both
symptoms and global levels of impairment. While generally
well tolerated stimulant medication has a range of side-
effects in a substantial minority of children [4, 6, 30].
Understanding the impact of mental disorder in general
and ADHD in particular on QoL can be informative on a
number of levels. QoL has the potential to be an important
outcome measure. Indeed Spitzer and colleagues have
Eur Child Adolesc Psychiatry (2010) 19:83–105 85
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suggested that the main goal of healthcare is to improve
patients perceptions of their health and the extent to which
health problems interfere with their QoL [79]. It could be
argued that QoL outweighs simple short-term symptom
reduction as the most important treatment outcome for
ADHD. If a treatment reduces symptoms but does not
increase a child’s QoL can that treatment be considered
effective? Thus QoL, if able to be measured reliably could
be an important outcome measure in both clinical research
and routine patient care. On a more general level the use of
QoL data by individual child and adolescent mental health
services could assist with service planning and audit—and
help focus attention on outcomes that patients themselves
feel are important. Taking this one step further the
assessment of QoL across different mental and physical
health domains can allow for direct comparisons to be
made between the impacts of these conditions on either
individuals or populations—which in turn has the potential
to provide an evidence base for a more rational reconsid-
eration of the ways that resources are allocated within
health services than is typically the case. QoL measure-
ment is already acknowledged as being central to the cal-
culation of cost-effectiveness of different treatments and
hence to the choices between treatments, both at an eco-
nomic level (e.g. reimbursement of drug treatment costs)
and at an individual patient level [21].
In order that these goals can be achieved, with respect to
ADHD, several key questions need to be addressed. These
include; (1) what is the impact of ADHD on QoL? (2)
What are the relationships between ADHD symptoms,
functional impairment and the mediators and moderators of
QoL in ADHD? (3) Does the treatment of ADHD impact
on QoL? This paper will address progress to date in trying
to find answers to these questions through a systematic
review of the published literature pertaining to QoL in
ADHD, identify gaps in knowledge and make suggestions
about the future lines of investigation that will be required
to further the field.
Methods
A systematic literature search was conducted using the
following databases; Ovid MEDLINE (R), Cochrane
database of systematic reviews, ACP Journal Club,
DARE, CCTR, CMR, HTA, NHSEED, EMBASE and
PsychINFO from 1988 to April 2008. Text word and
thesaurus searches were used to minimize the chance of
missing relevant articles. The following keywords were
searched: child, childhood, children, pediatric, paediatric,
adolescent; quality of life, QOL, HRQOL, health status,
functional status, well-being; self-esteem, self-concept,
self-competence and self-image; ADHD, Attention deficit
hyperactivity disorder, attention 9 disorder. The reference
lists of identified papers and previous reviews of QoL in
children were searched manually. Included were papers in
one of five major European languages (English, German,
French, Italian, Spanish). Other inclusion criteria were;
publication in a peer reviewed journal; a study, of any
design, focusing on QoL in children or adolescents with
ADHD that contained at least some empirical data on
QoL measurement in children or adolescents with ADHD
and used a QoL instrument. Studies in adults were
excluded. The titles and abstracts of all papers identified
from the first search were read by two authors (MD, DC)
where there was disagreement at this stage the paper was
retained. The full text of those papers passing this screen
was read independently by two of the authors (MD, DC).
There was full agreement between these two authors at
this stage. Data was extracted by MD and checked for
accuracy by DC and E S–B. Where there were several
publications from single studies these were included
where there was not repetition in the data presented.
Where there were meta-analyses these were included and
discussed before the individual studies.
The results of identified studies are described in a
descriptive manner with effect sizes reported where avail-
able. As a guide to interpreting the clinical meanings of
these effect sizes Norman et al. [53] proposed that, in QoL
research, a difference of at least half a standard deviation is
required for a ‘‘clinically meaningful difference.’’
Results
This broad search strategy resulted in a total of 1,445
articles (including duplicates) from which a total of 36
relevant articles were identified (Fig. 1, Tables 1, 2).
Potentially Relevant Studies 
Identified and Screened for Retrieval 
N = 1445 
Studies Retrieved for more detailed 
evaluation
N = 72 
Excluded after reading title and 
abstract
Not QoL n = 441 
Not ADHD n = 399 
No Empirical Data n = 314 
Adult Studies n = 176 
Non European Language n = 43 
Studies Included in the Review 
N = 36 
Excluded after Reading Paper 
Not QoL = 15 
Not ADHD N = 11 
No empirical data n = 1 
Adult Studies N = 2 
Duplicates n = 7 
Fig. 1 QUOROM flow chart for literature search
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ti
o
n
-d
efi
ci
t
h
ad
a
b
et
te
r
em
o
ti
o
n
al
fu
n
ct
io
n
in
g
sc
o
re
th
an
ch
il
d
re
n
w
it
h
an
x
ie
ty
d
is
o
rd
er
s.
T
h
ei
r
ac
ad
em
ic
p
er
fo
rm
an
ce
w
as
si
g
n
ifi
ca
n
tl
y
lo
w
er
th
an
fo
r
ch
il
d
re
n
w
it
h
an
x
ie
ty
d
is
o
rd
er
s
an
d
o
th
er
d
is
o
rd
er
s.
P
sy
ch
ia
tr
ic
co
m
o
rb
id
it
y
d
id
n
o
t
in
fl
u
en
ce
o
v
er
al
l
Q
o
L
K
la
ss
en
et
al
.
[3
8
]
C
ro
ss
se
ct
io
n
al
C
H
Q
P
ar
en
t
1
3
1
A
D
H
D
co
m
p
ar
ed
to
n
o
rm
s
C
h
il
d
re
n
w
it
h
A
D
H
D
h
ad
co
m
p
ar
ab
le
p
h
y
si
ca
l
h
ea
lt
h
b
u
t
cl
in
ic
al
ly
im
p
o
rt
an
t
d
efi
ci
ts
in
al
l
p
sy
ch
o
so
ci
al
Q
o
L
d
o
m
ai
n
s.
P
o
o
re
r
p
sy
ch
o
so
ci
al
Q
o
L
w
as
co
rr
el
at
ed
w
it
h
g
re
at
er
p
ar
en
t-
re
p
o
rt
ed
A
D
H
D
sy
m
p
to
m
s.
C
h
il
d
re
n
w
it
h
C
2
co
m
o
rb
id
d
is
o
rd
er
s
h
ad
w
o
rs
e
Q
o
L
th
an
th
o
se
w
it
h
n
o
co
m
o
rb
id
it
y
in
m
o
st
ar
ea
s
an
d
fr
o
m
th
o
se
w
it
h
1
co
m
o
rb
id
d
is
o
rd
er
in
3
d
o
m
ai
n
s.
P
re
d
ic
to
rs
o
f
p
sy
ch
o
so
ci
al
h
ea
lt
h
in
cl
u
d
ed
th
e
n
u
m
b
er
o
f
co
m
o
rb
id
co
n
d
it
io
n
s
an
d
p
ar
en
t
ra
te
d
co
m
b
in
ed
A
D
H
D
sy
m
p
to
m
s
M
at
za
et
al
.
[4
5
]
B
as
el
in
e
d
at
a
fr
o
m
an
R
C
T
:
A
T
X
v
er
su
s
P
la
ce
b
o
C
H
Q
P
ar
en
t
2
9
7
A
D
H
D
Q
o
L
sc
o
re
s
w
er
e
si
g
n
ifi
ca
n
tl
y
lo
w
er
th
an
n
at
io
n
al
n
o
rm
s
an
d
w
er
e
n
eg
at
iv
el
y
co
rr
el
at
ed
w
it
h
cl
in
ic
al
m
ea
su
re
s
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T
a
b
le
1
co
n
ti
n
u
ed
R
ef
er
en
ce
D
es
ig
n
M
ea
su
re
R
at
er
N
M
ai
n
o
u
tc
o
m
es
T
o
p
o
ls
k
i
et
al
.
[8
2
]
C
ro
ss
se
ct
io
n
al
Y
Q
O
L
-R
Y
o
u
n
g
p
er
so
n
5
5
A
D
H
D
,
5
2
m
o
b
il
it
y
im
p
ai
rm
en
t,
1
0
7
h
ea
lt
h
y
co
n
tr
o
ls
T
h
e
ad
o
le
sc
en
ts
w
it
h
A
D
H
D
re
p
o
rt
ed
si
g
n
ifi
ca
n
tl
y
lo
w
er
Q
o
L
sc
o
re
s
th
an
th
e
h
ea
lt
h
y
co
n
tr
o
l
g
ro
u
p
(p
ar
ti
cu
la
rl
y
in
th
e
S
el
f
an
d
R
el
at
io
n
sh
ip
d
o
m
ai
n
s)
an
d
si
m
il
ar
sc
o
re
s
to
th
o
se
fr
o
m
th
e
g
ro
u
p
w
it
h
m
o
b
il
it
y
im
p
ai
rm
en
t
(a
g
ro
u
p
p
re
v
io
u
sl
y
d
em
o
n
st
ra
te
d
to
h
av
e
re
d
u
ce
d
Q
o
L
)
B
as
ti
aa
n
se
n
et
al
.
[8
]
L
o
n
g
it
u
d
in
al
st
u
d
y
in
cl
in
ic
al
ly
re
fe
rr
ed
ch
il
d
re
n
w
it
h
p
sy
ch
ia
tr
ic
d
is
o
rd
er
P
ed
sQ
L
P
ar
en
t
1
2
6
R
ef
er
re
d
ch
il
d
re
n
,
4
8
A
D
H
D
3
8
%
o
f
ch
il
d
re
n
sh
o
w
ed
n
ei
th
er
sy
m
p
to
m
re
d
u
ct
io
n
n
o
r
Q
o
L
im
p
ro
v
em
en
t,
3
3
%
o
f
ch
il
d
re
n
sh
o
w
ed
b
o
th
a
cl
in
ic
al
ly
sy
m
p
to
m
re
d
u
ct
io
n
an
d
Q
o
L
im
p
ro
v
em
en
t.
In
1
1
%
o
f
al
l
ch
il
d
re
n
,
Q
o
L
im
p
ro
v
ed
w
h
il
e
th
e
le
v
el
o
f
p
sy
ch
o
p
at
h
o
lo
g
y
re
m
ai
n
ed
h
ig
h
an
d
in
1
8
%
p
sy
ch
o
p
at
h
o
lo
g
y
im
p
ro
v
ed
w
h
il
e
th
e
le
v
el
o
f
Q
o
L
re
m
ai
n
ed
h
ig
h
E
sc
o
b
ar
et
al
.
[2
6
]
C
as
e
co
n
tr
o
l
C
H
Q
P
ar
en
t
1
2
0
A
D
H
D
;
9
3
as
th
m
a;
1
2
0
h
ea
lt
h
y
C
h
il
d
re
n
w
it
h
A
D
H
D
w
er
e
ra
te
d
w
o
rs
e
th
an
ei
th
er
as
th
m
at
ic
o
r
h
ea
lt
h
y
ch
il
d
re
n
fo
r
m
o
st
C
h
il
d
H
ea
lt
h
Q
u
es
ti
o
n
n
ai
re
d
o
m
ai
n
s.
T
h
e
g
re
at
es
t
d
if
fe
re
n
ce
s
w
er
e
fo
u
n
d
in
b
eh
av
io
u
r,
so
ci
al
li
m
it
at
io
n
s
at
tr
ib
u
ta
b
le
to
p
h
y
si
ca
l
p
ro
b
le
m
s,
em
o
ti
o
n
al
im
p
ac
t
o
n
p
ar
en
ts
,
an
d
fa
m
il
y
ac
ti
v
it
ie
s
M
at
za
et
al
.
[4
6
]
C
ro
ss
se
ct
io
n
al
C
H
Q
,
C
H
IP
-C
E
,
E
Q
-5
D
P
ar
en
t
1
2
6
A
D
H
D
E
Q
-5
D
sc
o
re
s
w
er
e
co
rr
el
at
ed
w
it
h
se
v
er
al
d
o
m
ai
n
s
o
f
th
e
C
H
Q
-P
F
5
0
(e
.g
.
M
en
ta
l
H
ea
lt
h
,
S
el
f-
E
st
ee
m
,
F
am
il
y
A
ct
iv
it
ie
s,
P
sy
ch
o
so
ci
al
S
u
m
m
ar
y
S
co
re
)
th
e
C
H
IP
-C
E
(e
.g
.
S
at
is
fa
ct
io
n
,
C
o
m
fo
rt
,
A
ca
d
em
ic
P
er
fo
rm
an
ce
,
P
ee
r
R
el
at
io
n
s)
an
d
th
e
A
D
H
D
-R
S
sc
al
es
M
at
za
et
al
.
[4
7
]
C
ro
ss
se
ct
io
n
al
S
ta
n
d
ar
d
g
am
b
le
u
ti
li
ty
in
te
rv
ie
w
s
P
ar
en
t
4
3
A
D
H
D
C
o
m
p
ar
is
o
n
s
b
et
w
ee
n
th
e
v
ar
io
u
s
h
ea
lt
h
st
at
es
fo
u
n
d
th
e
ex
p
ec
te
d
d
if
fe
re
n
ce
s
b
et
w
ee
n
u
n
tr
ea
te
d
m
il
d
,
m
o
d
er
at
e,
an
d
se
v
er
e
A
D
H
D
h
ea
lt
h
st
at
es
su
g
g
es
ti
n
g
th
at
p
ar
en
t
st
an
d
ar
d
g
am
b
le
in
te
rv
ie
w
s
ar
e
a
fe
as
ib
le
an
d
u
se
fu
l
m
et
h
o
d
fo
r
o
b
ta
in
in
g
u
ti
li
ty
in
A
D
H
D
N
ew
co
rn
et
al
.
[5
2
]
B
as
el
in
e
d
at
a
fr
o
m
an
R
C
T
:
A
T
X
v
er
su
s
P
la
ce
b
o
C
H
Q
P
ar
en
t
2
9
3
A
D
H
D
3
9
%
w
it
h
O
D
D
Y
o
u
th
s
w
it
h
A
D
H
D
an
d
w
it
h
o
u
t
co
m
o
rb
id
O
D
D
h
ad
re
d
u
ce
d
Q
o
L
co
m
p
ar
ed
to
co
n
tr
o
ls
.
Q
o
L
w
as
lo
w
er
in
th
o
se
w
it
h
co
m
o
rb
id
O
D
D
P
o
n
g
w
il
ai
ra
t
et
al
.
[5
9
]
C
as
e
co
n
tr
o
l
P
ed
sQ
L
C
h
il
d
,
p
ar
en
t
4
6
A
D
H
D
,
9
4
h
ea
lt
h
y
ch
il
d
re
n
B
o
th
th
e
ch
il
d
re
n
w
it
h
A
D
H
D
an
d
th
ei
r
p
ar
en
ts
re
p
o
rt
ed
a
si
g
n
ifi
ca
n
tl
y
lo
w
er
p
sy
ch
o
so
ci
al
Q
o
L
sc
o
re
s
th
an
co
n
tr
o
ls
an
d
th
ei
r
p
ar
en
ts
.
C
h
il
d
re
n
w
it
h
A
D
H
D
al
so
re
p
o
rt
ed
th
em
se
lv
es
to
h
av
e
a
si
g
n
ifi
ca
n
tl
y
lo
w
p
h
y
si
ca
l
Q
o
L
sc
o
re
,
d
es
p
it
e
b
ei
n
g
ad
ju
d
g
ed
to
b
e
p
h
y
si
ca
ll
y
h
ea
lt
h
y
R
en
tz
et
al
.
[6
4
]
B
as
el
in
e
d
at
a
fr
o
m
an
R
C
T
C
H
Q
P
ar
en
t
9
2
1
A
D
H
D
In
te
rn
al
co
n
si
st
en
cy
(C
h
ro
n
b
ac
h
’s
al
p
h
a)
at
b
as
el
in
e
w
as
0
.8
8
fo
r
th
e
P
sy
ch
o
so
ci
al
S
u
m
m
ar
y
S
co
re
,
ra
n
g
in
g
fr
o
m
0
.5
3
to
0
.9
1
fo
r
th
e
su
b
sc
al
e
sc
o
re
s.
C
o
n
st
ru
ct
v
al
id
it
y
w
as
su
p
p
o
rt
ed
.
S
ca
le
s
w
er
e
re
sp
o
n
si
v
e
to
ch
an
g
e
S
ec
n
ik
et
al
.
[7
6
]
C
ro
ss
se
ct
io
n
al
E
Q
-5
D
,
st
an
d
ar
d
g
am
b
le
u
ti
li
ty
in
te
rv
ie
w
s
P
ar
en
t
8
3
A
D
H
D
P
ar
en
ts
’
ra
w
S
G
sc
o
re
s
o
f
th
ei
r
ch
il
d
’s
cu
rr
en
t
h
ea
lt
h
st
at
e
w
er
e
si
g
n
ifi
ca
n
tl
y
co
rr
el
at
ed
w
it
h
in
at
te
n
ti
v
e,
h
y
p
er
ac
ti
v
e,
an
d
o
v
er
al
l
A
D
H
D
sy
m
p
to
m
s
an
d
th
e
E
Q
-5
D
v
is
u
al
an
al
o
g
u
e
sc
al
e
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T
a
b
le
1
co
n
ti
n
u
ed
R
ef
er
en
ce
D
es
ig
n
M
ea
su
re
R
at
er
N
M
ai
n
o
u
tc
o
m
es
H
am
p
el
an
d
D
es
m
an
[3
3
]
C
ro
ss
se
ct
io
n
al
K
id
-K
IN
D
L
-R
C
h
il
d
4
8
A
D
H
D
co
m
p
ar
ed
to
n
o
rm
s
A
ll
d
o
m
ai
n
s
o
f
q
u
al
it
y
o
f
li
fe
w
er
e
im
p
ai
re
d
am
o
n
g
ch
il
d
re
n
an
d
ad
o
le
sc
en
ts
w
it
h
A
D
H
D
co
m
p
ar
ed
to
n
o
rm
at
iv
e
d
at
a
K
la
ss
en
et
al
.
[3
9
]
C
ro
ss
se
ct
io
n
al
C
H
Q
C
h
il
d
,
p
ar
en
t
5
8
A
D
H
D
C
o
m
p
ar
ed
w
it
h
p
o
p
u
la
ti
o
n
n
o
rm
s,
ac
ro
ss
m
o
st
d
o
m
ai
n
s,
ch
il
d
re
n
w
it
h
A
D
H
D
re
p
o
rt
ed
co
m
p
ar
ab
le
h
ea
lt
h
.
C
h
il
d
re
n
ra
te
d
th
ei
r
Q
O
L
si
g
n
ifi
ca
n
tl
y
b
et
te
r
th
an
th
ei
r
p
ar
en
ts
in
fo
u
r
ar
ea
s
(b
eh
av
io
u
r,
se
lf
-e
st
ee
m
,
m
en
ta
l
h
ea
lt
h
an
d
fa
m
il
y
co
h
es
io
n
),
an
d
si
g
n
ifi
ca
n
tl
y
p
o
o
re
r
fo
r
o
n
e
(P
h
y
si
ca
l
F
u
n
ct
io
n
).
C
o
rr
el
at
io
n
s
b
et
w
ee
n
ch
il
d
re
n
an
d
p
ar
en
ts
w
er
e
re
la
ti
v
el
y
lo
w
.
D
is
cr
ep
an
ci
es
b
et
w
ee
n
p
ar
en
t-
ch
il
d
ra
ti
n
g
s
w
er
e
re
la
te
d
to
th
e
p
re
se
n
ce
o
f
a
co
m
o
rb
id
o
p
p
o
si
ti
o
n
al
/
d
efi
an
t
d
is
o
rd
er
,
a
p
sy
ch
o
so
ci
al
st
re
ss
o
r
an
d
in
cr
ea
se
d
A
D
H
D
sy
m
p
to
m
s
R
al
st
o
n
et
al
.
[6
1
]
C
ro
ss
se
ct
io
n
al
C
H
IP
-C
E
P
ar
en
t
1
,4
7
8
A
D
H
D
,
m
ed
ic
at
io
n
n
ai
v
e
S
ig
n
ifi
ca
n
t
im
p
ai
rm
en
ts
o
n
al
l
C
H
IP
-C
E
d
o
m
ai
n
s;
(s
at
is
fa
ct
io
n
,
co
m
fo
rt
,
re
si
li
en
ce
,
ri
sk
av
o
id
an
ce
an
d
ac
h
ie
v
em
en
t
R
il
ey
et
al
.
[6
5
]
C
ro
ss
se
ct
io
n
al
C
H
IP
-C
E
P
ar
en
t
1
,4
7
7
A
D
H
D
,
m
ed
ic
at
io
n
n
ai
v
e
In
te
rn
al
co
n
si
st
en
cy
re
li
ab
il
it
y
w
as
g
o
o
d
-t
o
-e
x
ce
ll
en
t
(C
h
ro
n
b
ac
h
’s
al
p
h
a
[
0
.7
0
)
fo
r
al
l
C
H
IP
-C
E
d
o
m
ai
n
s
an
d
su
b
d
o
m
ai
n
s,
w
it
h
al
m
o
st
n
o
ce
il
in
g
an
d
fl
o
o
r
ef
fe
ct
s.
F
ac
to
r
an
al
y
si
s
w
as
b
ro
ad
ly
su
p
p
o
rt
iv
e
o
f
th
e
o
ri
g
in
al
st
ru
ct
u
re
w
it
h
m
in
o
r
ad
ju
st
m
en
ts
.
C
H
IP
-C
E
sc
al
es
w
er
e
m
o
d
er
at
e-
to
-h
ig
h
ly
co
rr
el
at
ed
w
it
h
m
ea
su
re
s
o
f
A
D
H
D
an
d
fa
m
il
y
fa
ct
o
rs
R
il
ey
et
al
.
[6
8
]
C
ro
ss
se
ct
io
n
al
C
H
IP
-C
E
P
ar
en
t
1
,4
7
8
A
D
H
D
,
m
ed
ic
at
io
n
n
ai
v
e
F
ac
to
rs
si
g
n
ifi
ca
n
tl
y
as
so
ci
at
ed
w
it
h
a
p
o
o
re
r
Q
o
L
in
cl
u
d
ed
;
A
D
H
D
sy
m
p
to
m
s,
co
n
d
u
ct
p
ro
b
le
m
s,
p
ee
r
re
la
ti
o
n
sh
ip
p
ro
b
le
m
s,
h
av
in
g
as
th
m
a,
m
u
lt
ip
le
o
th
er
so
m
at
ic
sy
m
p
to
m
s,
co
-o
rd
in
at
io
n
p
ro
b
le
m
s,
fa
m
il
y
fa
ct
o
rs
(h
av
in
g
a
p
ar
en
t
w
it
h
a
h
ea
lt
h
o
r
m
en
ta
l
h
ea
lt
h
p
ro
b
le
m
p
o
ss
ib
ly
ca
u
se
d
b
y
th
e
ch
il
d
’s
il
ln
es
s,
ch
il
d
n
o
t
li
v
in
g
w
it
h
b
o
th
p
ar
en
ts
an
d
m
at
er
n
al
sm
o
k
in
g
d
u
ri
n
g
p
re
g
n
an
cy
)
V
ar
n
i
an
d
B
u
rw
in
k
le
[8
3
]
V
al
id
at
io
n
fr
o
m
cr
o
ss
se
ct
io
n
al
p
o
p
u
la
ti
o
n
sa
m
p
le
P
ed
sQ
L
C
h
il
d
/y
o
u
n
g
p
er
so
n
,
p
ar
en
t
7
2
A
D
H
D
,
6
6
ca
n
ce
r,
5
7
ce
re
b
ra
l
p
al
sy
,
3
,2
5
6
h
ea
lt
h
y
co
n
tr
o
ls
G
o
o
d
re
li
ab
il
it
y
fo
r
th
e
to
ta
l
sc
al
e
sc
o
re
(C
h
ro
n
b
ac
h
’s
al
p
h
a
=
0
.9
2
ch
il
d
se
lf
-r
ep
o
rt
,
0
.9
2
p
ar
en
t
p
ro
x
y
-r
ep
o
rt
).
D
is
ti
n
g
u
is
h
ed
b
et
w
ee
n
h
ea
lt
h
y
ch
il
d
re
n
an
d
ch
il
d
re
n
w
it
h
A
D
H
D
.
C
h
il
d
re
n
w
it
h
A
D
H
D
se
lf
-r
ep
o
rt
ed
se
v
er
el
y
im
p
ai
re
d
p
sy
ch
o
so
ci
al
fu
n
ct
io
n
in
g
,
co
m
p
ar
ab
le
to
ch
il
d
re
n
w
it
h
n
ew
ly
d
ia
g
n
o
se
d
ca
n
ce
r
an
d
ch
il
d
re
n
w
it
h
ce
re
b
ra
l
p
al
sy
H
ak
k
aa
rt
-v
an
R
o
ij
en
et
al
.
[3
2
]
C
as
e
co
n
tr
o
l
C
H
Q
P
ar
en
t
7
0
A
D
H
D
,
3
5
ch
il
d
re
n
w
it
h
n
o
n
-A
D
H
D
b
eh
av
io
u
r
p
ro
b
le
m
s,
6
0
h
ea
lt
h
y
co
n
tr
o
ls
N
o
si
g
n
ifi
ca
n
t
d
if
fe
re
n
ce
s
b
et
w
ee
n
th
e
g
ro
u
p
s
o
n
th
e
p
h
y
si
ca
l
su
m
m
ar
y
sc
o
re
.
A
D
H
D
p
at
ie
n
ts
sc
o
re
d
si
g
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All except one of these papers described ratings made
with generic measures of QoL. The nine generic measures
used were; the Child Health Questionnaire [CHQ, 42], the
Pediatric Quality of Life Inventory [PedsQL, 85], the Child
Health Illness Profile-Child Edition [CHIP-CE, 66, 67], the
Youth Quality of Life Instrument-Research Version
[YQOL-R, 56], the Munich Quality of Life Questionnaire
for Children [KINDL, 62], the Dutch Child AZL TNO
Quality of Life [DUX-25, 40], the TNO AZL Child Quality
of Life [TACQOL, 87], the EuroQoL Five-Dimension
Questionnaire (EQ-5D, EuroQol Group 1990) and the
Global Impression of Perceived Difficulties [GIPD, 88, 89].
All of these measures have been demonstrated to have
acceptable psychometric properties. Having examined
these instruments we feel that, notwithstanding the fact that
authors of the GIPD have presented data supporting the
reliability and validity data of their scale, the validity of the
GIPD as a true measure of QoL is questionable as it is very
general in nature. There are only five questions each of
which asks about difficulties in a particular situation (in the
morning, during school, during homework, in the evening,
and overall difficulties) e.g. ‘‘Considering the past seven
days, how difficult has the time spent in school been for
you?’’ In view of these issues data related to the GIPD is
not discussed further.
The disorder-specific measure was the ADHD Impact
Module [AIM, 43] which has been psychometrically
validated [43] but has not been subsequently used in any
published studies. A second disorder-specific scale The
Weiss Functional Impairment Rating Scale has been
developed and initial studies suggest that it has strong
internal consistency, a well established domain structure
and is sensitive to change following treatment [90].
Correlations with the CHIP-CE (a broad based general
measure of QoL) domains ranged from -0.32 to -0.72
(Weiss, personal communication). Although the Weiss
scale was designed to focus on functional impairment it
shares many similarities with measures of QoL. Studies
using the Weiss scale are ongoing but have not yet been
published.
Unfortunately the majority of studies in relation to child
mental health in general and ADHD in specific have used
only parent/carers as informants and not asked the child
themselves about their QoL. Of the papers in this review 29
included only parent ratings, 2 included only child/young
person ratings, and five included both parent and child
ratings.
What is the impact of ADHD on QoL?
Identified case control and cross sectional studies of QoL in
ADHD are described in Table 1.T
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QoL in children with ADHD compared to healthy
children
With two exceptions [75, 83] all of the studies which have
investigated QoL in children or adolescents with ADHD
have been conducted using clinical samples of referred
children.
Self-report
Despite the considerable importance invested in the indi-
vidual’s self-perceptions by most definitions of QoL, only
7 studies of the QoL of children with ADHD that included
child ratings were identified. Two studies used the CHQ,
both of which failed to find a difference between ADHD
and controls. Landgraf and Abetz [41] found that children
with ADHD (9–16 years) reported their QoL to be very
similar to that of healthy controls across the nine domains
of the self-report version of the CHQ-CF87. Klassen et al.
[39] also found that children and adolescents with ADHD
(10–17 years old) rated their own QoL as no different from
the general child population across most of the CHQ-CF87
domains. Compared to a healthy control group they con-
sidered themselves to be equal with respect to overall QoL,
and on the role/social functioning, general health percep-
tions, bodily pain/discomfort, mental health, self-esteem
and parental impact, slightly worse for physical function
and behaviour and significantly worse only for family
activities. The Klassen et al. study also compared child and
parent CHQ ratings. Children rated their QoL significantly
more positively than did their parents for their behaviour,
self-esteem, mental health and family cohesion and sig-
nificantly poorer for physical function. In general there was
greater agreement between children and their parents for
the physical subscales (with correlations between r = 0.75
and r = 0.60) than for the psychosocial subscales (between
r = 0.40 and r = 0.48). Using the KINDL [62], Hampel
and Desman [33] also found all domains of quality of life
to be impaired in children and adolescents with ADHD
compared to normative data.
In contrast to these findings with the CHQ and the
KINDL several studies using different measures did find
that children with ADHD self-report reduced QoL com-
pared to healthy children. Topolski et al. [82] using the
YQOL-R [22, 56], found that adolescents with ADHD
(11–18 years) reported poorer QoL, compared with a
control group without a chronic health condition, especially
in the domains of self (belief in self, mental and physical
health) and relationships (peers, friends, family, adults).
These differences were no longer statistically significant,
however, when a Bonferroni correction for multiple com-
parisons was applied. Pongwilairat et al. [59] using the
PedsQL [86], in a Thai sample also found lower self rated
QoL in children with ADHD. The total score and the
physical and psychosocial domain scores on the PedsQL
reported by children with ADHD were all significantly
lower than those reported by control children. These dif-
ferences remained when corrected for medication status.
Varni and Burwinkle [83] also found that, compared to
healthy children, ADHD children (5–16 years) reported
significantly lower PedsQL scores on dimensions of psy-
chosocial health and small, but not statistically significant
differences on physical functioning in a large population-
based study. They also reported that the parent and child
ratings were similar across all domains, that the inter-cor-
relations of the PedsQL subscales between the two raters
were in the medium to large range (between r = 0.50 and
r = 0.75), and that the correlations in the physical domain
were similar to those for the psychosocial domains [83].
Rimmer et al. [69] reported similar correlations (r = 0.67)
between child and parent ratings on the PedsQL in an
independent clinic based sample. Using the DUX-25 [40]
and TACQOL [87] in a Dutch clinical sample of children
with both ADHD and developmental coordination disorder
(DCD) Flapper et al. [28] also found lower overall QoL in
the ADHD/DCD group on both measures with subscale
scores on the DUX-25 demonstrating lower functioning on
the emotional and social domains and the TACQOL lower
functioning on the motor, autonomy, cognitive, social and
positive moods domains.
Parent rated
Twenty-three studies were identified that compared parent
rated QoL in samples of children and adolescents with
ADHD with that of normal controls or against existing
normative data on QoL from standardized instruments.
During the development of the parent version of the Child
Health Questionnaire (CHQ-PF50), Landgraf et al. [42]
reported that an ADHD sample were rated as having sig-
nificantly lower scores on the psychosocial summary score
and the psychosocial and family subscales (behaviour,
mental health, self-esteem, role limitations-emotional/
behavioural, parental impact-emotional and time, family
activities and family cohesion), compared to their norm
group. These findings were replicated in several clinical
ADHD samples which used the CHQ and compared chil-
dren with ADHD to either healthy controls [26, 32, 75] or
US norms [15, 38, 39, 45, 46, 52, 57, 58, 64, 97]. Differ-
ences have been reported for both male and female sub-
jects. The largest differences have been found on the
family impact (family activities, parental time emotional),
behaviour and role-emotional/behavioural subscales. The
psychosocial summary scores for children with ADHD in
the different studies are between 1.5 and 2 SD below the
US norms. Comparing different ADHD-subtypes on the
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CHQ, all three subtypes had worse scores than controls on
most subscales although only the inattentive subtype were
impaired on the physical subscales. There were other dif-
ferences between the groups, for example, the combined
and inattentive subtypes had significantly lower scores on
the self-esteem and emotional impact subscales than the
hyperactive-impulsive type and the combined subtype in
turn showed worse scores on the, role/social functioning
(due to emotional and behavioural problems, family
activities and impact on parental time subscales than both
the inattentive and hyperactive-impulsive subtypes [29].
Parents did not rate children with ADHD to have lower
QoL on the physical domain in most studies [38, 45, 57,
64]. However, in a large community sample Sawyer et al.
[75] did find small but significant differences on the parent-
reported physical subscales of the CHQ-and the study of
Escobar et al. [26] also reported a significantly lower
physical summary score in children with newly diagnosed
ADHD, compared to a control sample. Klassen [37] com-
puted the effect sizes for several of the above studies, using
the CHQ-PF 50 using the criterion of Norman et al. [53]
clinically meaningful deficits in QoL were reported on all
psychosocial and family subscales (mental health -0.55,
self-esteem -0.75, parental impact time -0.85, role-
emotional/behavioural -1.22, behaviour -1.44, parental
impact-emotions, -1.45 and family activities -1.67).
Using the PedsQL both Pongwilairat et al. [59] and
Varni and Burwinkle [83] found children with ADHD to
have similar parent rated QoL for physical health compared
to healthy controls. This contrasts with the lower total and
psychosocial, emotional, social and school subscale scores
on the ratings of the ADHD group reported in the same
studies.
In a pan-European ADHD observational study [ADORE,
59], the QoL of some 1,500 children with ADHD was
dramatically lower at baseline, than that of norms for
community youth, with mean scores on the parent report
form of the CHIP-CE [67] between 1.5 and 2 standard
deviations below community norms in all domains, except
for the comfort domain. Scores were below 35 (mean of 50
with SD of 10) for the sub-domains, satisfaction with self,
social problem solving, threats to achievement and aca-
demic achievement and between 40 and 35 for satisfaction
with health, emotional comfort, family involvement, indi-
vidual risk avoidance and peer relations. Only three sub-
domains were near normal: physical comfort, restricted
activities and physical activities. These findings were con-
sistent across all ten participating countries [65]. Equally
compromised QoL, as measured by the CHIP-CE, was
found in 200 children with ADHD entering an open label
treatment study in the UK [60].
Hampel and Desman [33] found all domains of parent
reported QoL to be impaired among children and
adolescents with ADHD compared to normative data using
the KINDL [62] and Flapper et al. [28] also reported
reduced overall parent rated QoL in their group of children
with ADHD and DCD on both the parent rated DUX-25
[40] and TACQOL [87] measures with subscale scores on
the DUX-25 demonstrating lower functioning on the
physical, home, emotional and social domains and the
TACQOL lower functioning on the motor, autonomy,
cognitive, social and positive and negative moods domains.
In two linked studies, one in the UK and one in the US,
that used the EQ-5D parent version [27], very few of the
parents of children with ADHD-related problems reported
difficulties on the physical items (e.g. mobility and pain/
discomfort) while the majority endorsed that their children
had problems with emotions and in their abilities to carry
out usual activities [46].
In summary, robust reductions in QoL of around 1.5–2.0
SD are reported across several different QoL measures and
across a broad range of psycho-social, achievement and
self evaluation domains by the parents of children with
ADHD. Clearly these are large effects which are similar in
size to those reported for the ADHD symptoms [93]. In
general no strong effects of ADHD on physical functioning
domain of QoL are reported. This negative impact is seen
in both boys and girls and across the different ADHD-
subtypes. Although not well studied the impact of ADHD
on QoL appears to be less robust and broadly based when
self-reported QoL is the main outcome. Children with
ADHD rate their own QoL less negatively than do their
parents and do not always consider themselves as having
impaired QoL compared to healthy controls. These dif-
ferences between parents and children may be related to the
measures used. It is notable that while no group differences
were reported for the two studies that have used the CHQ
reduced self-reported QoL was reported in the four studies
in which other QoL measures were used. Comparative
studies would be helpful in identifying whether this is a
consequence of the limited number of studies or the way in
which the child completed CHQ has been constructed or
worded (the same pattern of results was not found for the
parent completed studies). However, it is also possible that
the less robust findings are due to either a lack of self
awareness or minimization of difficulties on the part of the
ADHD child cannot be ruled out. Alternatively parents’
ratings may be influenced by their own burden of care.
There clearly needs to be more effort put in to studying
self-reported QoL in those with ADHD and future studies
should consider comparing ratings across different mea-
sures and comparing and analyzing the differences between
child and parent ratings of QoL. It would also be of interest
to use interviews in parallel with the standard question-
naires to investigate the meaning of different QoL scores
and to tease out whether some questions are more sensitive/
94 Eur Child Adolesc Psychiatry (2010) 19:83–105
123
important at picking up problems than others in this group
of children and young people.
QoL in children with ADHD compared to children
with other conditions
In order to assess the significance of the effects of ADHD
on QoL it is useful to compare QoL in ADHD with QoL in
other physical and mental health conditions. Whilst it
would be possible to make indirect comparisons by com-
paring data from the many separate studies that have
investigated QoL in different conditions this would result
in a wide range of methodological problems. We have
therefore restricted ourselves to studies that have made
direct comparisons.
Three comparative studies have compared child self-
reported QoL in children with ADHD and other medical
conditions with conflicting results. Children with ADHD
rated their QoL far better than children with end stage renal
failure, not only on the physical subscales but also on role/
social behaviour and mental health using the CHQ-CF87
[41]. On the PedsQL children with ADHD reported; sig-
nificantly better physical functioning compared to children
with newly diagnosed cancer and children with cerebral
palsy; lower psychosocial health and social functioning (but
similar total scores and emotional and school functioning)
to the children with cancer and comparable total scores and
psychosocial, emotional, social and school functioning
to the children with cerebral palsy [83]. In the study by
Topolski et al. [82] adolescents with ADHD reported
similar scores on the YQOL-R to those from a group of
adolescents with mobility impairment, who had previously
been demonstrated to have reduced QoL compared to
healthy children. It is interesting to note that as in the
previous section, comparing child reported QoL between
children with ADHD and healthy controls, it was only the
study using the CHQ that reported the ADHD group to be
generally better than those in the physical problems group.
Several studies have used parent proxy measures of QoL
in comparative studies. Compared to children with asthma
and sickle cell disease, children with ADHD were rated as
having a lower QoL on the psychosocial subscales of the
CHQ-PR50 while being given better scores on the physical
subscales [45]. Escobar et al. [26] confirmed these findings
also using the CHQ in a comparison between children with
newly diagnosed ADHD and asthma. In the study of Varni
and Burwinkle [83] the pattern of impairments reported by
parents was different to that of the children themselves.
Whereas the children with ADHD had reported similar
total scores on the PedsQL to children with cancer and
cerebral palsy their parents rated their overall QoL as
superior to that reported by the parents of the two physical
disorder groups.
There have been several direct comparisons of parent
rated QoL between ADHD and other mental health con-
ditions. In a large community sample, the QoL of children
and adolescents with different mental disorders was com-
pared after the exclusion of comorbid cases [75]. The
results were all in the predicted direction. Children with
ADHD had more behavioural and fewer emotional prob-
lems than those with major depressive disorder, and also
had more interference with family activities and impact on
parental time (effect sizes all C0.3 SD). Interference with
peer and school activities or emotional impact on parents
varied little for children as a function of different mental
disorders. No significant differences were found between
children with ADHD and conduct disorder. In the same
study the scores of children with mental disorders (a
majority of who had ADHD) were significantly lower on
four of the five CHQ scales than for children with physical
disorders (including asthma, diabetes and epilepsy). In a
clinical sample, Bastiaansen et al. [7] did not find any
overall differences in QoL of children with ADHD/dis-
ruptive disorders compared to those with other psychiatric
disorders such as anxiety disorders, pervasive develop-
mental disorders, mood disorders or even to those for
whom help was being sought but who at assessment did not
warrant a formal psychiatric diagnosis. However, children
with disruptive disorders including ADHD showed signif-
icantly lower scores on the psychosocial sub-domain of the
PedsQL than children in the other or no diagnosis category.
Using the Dutch version of the CHQ PF-50 Hakkaart-van
Roijen et al. [32] found that parents of ADHD children
reported their children to have poorer QoL on the psy-
chosocial summary score compared to the reports of par-
ents of children with ‘‘non-ADHD behavioural problems.’’
In summary, ADHD has been shown to have a compa-
rable overall impact on QoL when compared to physical
disorders. However, a closer inspection suggests greater
impact on psychosocial QoL domains, and a lesser impact
on physical QoL domains than common chronic physical
illnesses. Initial evidence also suggests that ADHD has a
comparable overall impact on QoL when compared to
other mental health conditions. The available data is
starting to suggest that different mental health disorders
may impact on some QoL domains (e.g. peer and school
problems and impact on parents) in similar ways while on
other domains the impact varies depending on the disorder
(e.g. children with ADHD had more behavioural problems
and interference with family activities, but fewer emotional
problems than those with major depressive disorder).
However, data on these issues remains sparse and more
studies are required before any clear statements can be
made. Such data will be important not only to clinicians but
also to health service planners who are required to make
decisions about resource allocation between different parts
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of comprehensive children’s healthcare services and within
different parts of child and adolescent mental health
services.
Factors related to QoL in ADHD; Symptom severity,
impairment, comorbidity, demographic and other
factors
If we are to fully understand the nature of the QoL
impairments in ADHD it is necessary to examine the
factors that may drive a reduction in QoL.
Symptom severity
Several studies have investigated the correlations between
symptom severity and QoL scores. Clearly an absence of
correlation would be surprising and cast doubt on the rela-
tionship between ADHD and QoL. On the other hand a
perfect or very high correlation would lead one to question
whether the two concepts were in fact separable and whether
measuring QoL adds anything to our understanding of the
child with ADHD. A significant but moderately strong
correlation supports the notion that QoL and ADHD symp-
toms are related but distinct constructs and that both may be
required to give a full picture of a child’s difficulties.
The scores on the psychosocial scales of the CHQ-PF50
have been shown to significantly negatively correlate with
parent and clinician symptom ratings [38, 45, 64]. Corre-
lations are usually in the small to moderate range (between
r = –0.21 and r = -0.60), which suggests that these
measures are tapping into related but distinct constructs.
The highest correlations with symptom severity are found
on behaviour and family activities subscales. The psycho-
social subscales correlated equally highly with both the
hyperactivity/impulsivity and the inattention symptom
subscales [38, 45]. Correlations between the parent-repor-
ted QoL psychosocial scores and the teacher-reported
Child and Adolescent Symptom Inventory were not statis-
tically significant [38]. High symptom scores also predicted
poor QoL on parent ratings using the CHIP-CE in the
ADORE study [68]. Coghill et al. [19] using the EQ-5D
found that utility scores deteriorated as severity increased
and that patients with improved symptom severity since the
last consultation had higher utility values (0.88) than those
who did not improve (0.78). This suggested that patients
who had reduced symptom severity valued their health
state more than those whose symptoms did not improve.
Similar results were reported by Matza et al. [47]. Used
standard gamble (SG) utility interviews to assess parent
preferences for health states of childhood ADHD. Parents’
SG rating of their child’s current health state was signifi-
cantly correlated with inattentive, hyperactive, and overall
ADHD symptoms (r = 0.37, 0.36, and 0.40, respectively;
p \ 0.05) and psychosocial HRQL domains, the mean
utility score was 0.74 (on a utility scale ranging from 0 to
1). Secnik et al. [76] conducted a similar study in the UK
and again found that parents’ raw standard gamble scores
of their child’s current health state were significantly cor-
related with inattentive, hyperactive, and overall ADHD
symptoms and the EQ-5D visual analogue scale.
Functional impairment
While it is possible to have a serious physical disorders
such as diabetes, hypertension or cancer without there
being any obvious functional impairment for ADHD, and
most other psychiatric disorders, both symptoms and
functional impairment are a prerequisite for diagnosis.
Accordingly clinical guidelines have encouraged the
measurement of both and instruments such as the Chil-
dren’s Global Assessment Scale (CGAS) [77] have been
developed to allow impairment to be routinely measured in
a clinical setting [80]. There are both similarities and dif-
ferences between the concepts of impairment and QoL.
Impairment is an objectively measured assessment of a
deviation from the mean for a broad range of functional
domains. QoL relates to similar domains but measures
them subjectively against an internally rather than exter-
nally generated standard. Impairment is usually rated or
measured by the clinician, QoL by the patient; impairment
is integral to the illness; QoL is a broader assessment of the
impact of illness [75]. Some of these differences are
reflected in the differences between the CGAS and mea-
sures of QoL. As it involves making a single very general
rating the CGAS, would not be expected to capture the
diversity of QoL domains or the distinctiveness of the
parent or the child perspectives. Using the PedsQL Rimmer
et al. [69] found relatively low correlations between parent
and child ratings of QoL and clinician ratings of severity
using the CGAS (parent/clinician r = 0.42; child/clinician
r = 0.29). Poor scores on the Clinical Global Impressions
scale [CGI-S, 51], which indexes the severity of the dis-
order, were predictive of lower QoL as measured by parent
ratings on the CHIP-CE in the ADORE study [68]. It is
important to note that as some aspects of impairment are
heavily reliant on self or proxy reports (e.g. ability to keep
friends or build up close relationships) the boundaries
between the impairment and QoL constructs are not always
clear cut and much more work is required to more clearly
define their boundaries and overlaps. However, as is the
case for symptoms the finding of significant but not perfect
correlations between impairment and QoL in ADHD adds
some weight to the validity of the QoL construct in this
context and that QoL is not simply a relabelling of
impairment, as measured by tools like the CGAS, by a
different name.
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Comorbidity
Several studies have suggested that children with ADHD
and a comorbid disorder have poorer QoL than those with
ADHD alone. Newcorn et al. [52] compared youth with
ADHD with and without ODD, and found that those with
ODD generally had lower scores on the psychosocial
summary score of the CHQ-PF-50, as well as on most
subscales. The presence of a psychosocial stressor (e.g.
parental separation/divorce; move; conflict with siblings
or peers) was also related to a larger difference in the
behaviour scale in this study, and higher parent-reported
ADHD symptom severity was associated with more neg-
ative findings for self-esteem [52]. Within a sample of
clinically referred children with ADHD multiple comorbid
disorders was associated with poorer psychosocial QoL on
the CHQ-PF50 than having either no or only one comorbid
disorder [38]. The combination of comorbid ODD/CD and
another comorbid disorder (e.g. tic disorder, depression,
anxiety disorder but not learning disability) was also
associated with significantly lower scores [38]. In a sepa-
rate study by the same group discrepancies between parent
and child reports of the CHQ behaviour and mental health
scales were larger in the presence of ODD/CD [39].
In the ADORE study the association between 26 inde-
pendent factors including comorbid problems and ADHD
children’s QoL was investigated using the CHIP-CE [68].
The presence of high emotional symptoms, conduct prob-
lems, peer relationship problems, coordination problems,
asthma or two or more somatic symptoms, and having a
parent with mental health or health problems, were all
associated with poor parent-reported QoL on the CHIP-CE
over and above the association between ADHD and QoL.
Demographic and other factors
In the ADORE study several other baseline variables,
including several family factors, such as having a parent
with a health or mental health problem possibly caused by
the child’s illness, child not living with both parents and
maternal smoking during pregnancy were also associated
with poorer QoL. Other factors such as the number of
children living at home, a history of parental ADHD,
maternal drug/alcohol abuse during pregnancy and low
birth weight or prematurity were not associated with QoL
scores on any domain/sub-domain. Living with both par-
ents was, however, associated with a stronger sense of
well-being [68].
In summary, the available data supports the validity of
QoL measures as being associated with, but not com-
pletely overlapping with, ADHD symptomatology and
impairment. Increased symptom levels and impairment
predict poorer QoL. The presence of comorbid conditions
or psychosocial stressors is also predictive of poorer QoL
in samples of ADHD children. Further studies are
required to extend our understanding of the predictors and
correlates of reduced QoL. These data should also be
examined in detail to gain a better understanding of the
overlaps between the various frames of reference (symp-
toms, impairment and QoL) and this information fed back
so into efforts to refine the structure and scoring of cur-
rent measures and the development of new and improved
measures of QoL.
Is QoL in children with ADHD responsive
to treatment?
If QoL measures are to be useful as outcome measures it
is essential that they are sensitive and reliable measures
of, change and are able to and capture changes that may
occur in QoL after treatment. In their review of QoL
measures in children and adolescents Solans et al. [78]
reported that acceptable sensitivity to change has been
reported for only 10% of the identified generic instru-
ments (CHQ, KIDSCREEN, KINDL and Peds-QL).
However, those that were tested were found to be sensi-
tive to changes down to around 0.2 standard deviations.
Of these four measures only the CHQ and the Peds-QL
have so far been used in treatment studies of ADHD.
Studies in paediatrics have generally supported the use of
QoL as an outcome measure [84] although this remains a
relatively understudied field that has only become popular
to study in recent years. Within the child and adolescent
mental health field we believe that QoL has only been
used as an outcome in clinical trials for ADHD. The
studies that were identified which measured treatment
related changes in QoL in ADHD studies are described in
Table 2.
We are unaware of any published clinical trials of
psycho-social treatments for ADHD that have utilised QoL
measures of outcome. However, early data from the lon-
gitudinal aspect of the ADORE study do suggest that over
the first 3 months of treatment psychosocial treatments
(mainly psychoeducation) are associated with an
improvement in aspects of QoL, although these changes are
not as great as those seen for pharmacological treatments
[81].
Several studies have investigated the impact of medi-
cation treatments on QoL. Unfortunately as these studies
have only recently started to appear in the literature and
there are very few published studies describing the impact
of either methylphenidate or amfetamines on QoL. There
is, however, a fairly sizable literature on the effects of
atomoxetine on QoL. All currently published treatment
studies have used generic QoL scales rather than ADHD-
specific scales.
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Methylphenidate
There are no published controlled trials which have
investigated the impact of methylphenidate treatment on
QoL. In a cross sectional observational study of QoL, while
both stimulant medicated and un-medicated children with
ADHD had significantly lower total and psychosocial
subscales scores on the PedsQL than healthy controls and
these two groups did not differ from each other [59]. In
another observational study Yang et al. [97] using the
CHQ-PF50 also found the Psychosocial Summary Scores
and all of the psychosocial subscale scores of children
treated with methylphenidate were poor compared to
healthy controls. However, they also reported that
improvement of ADHD core symptoms after medication
treatment was predictive of higher psychosocial function-
ing. This effect was independent of the child’s current age,
age at receiving diagnosis, age starting and duration of
medication treatment but was not independent of ADHD
comorbidity: The QoL of those children with a comorbid
condition was less likely to improve even if core ADHD
improved [97]. Flapper et al. [28] investigated the effects
of methylphenidate at ‘‘optimal dose’’ in known responders
in an open label trial on the parent and child rated DUX-25
and TACQOL. Children on methylphenidate rated them-
selves and were rated by their parents as having improved
total QoL scores compared to their un-medicated state on
both instruments and improved scores on the child reported
physical and emotional subscales of the DUX-25, the child
reported autonomy, cognitive, social, and negative moods
subscales of the TACQOL and the parent-reported bodily,
motor, autonomy, cognitive and social subscales of the
TACQOL.
Amfetamines
One open label [71] and one randomized controlled dou-
ble-blind trial (RCT) [92] have investigated the impact of
mixed amfetamine salts on QoL. Both studies were spon-
sored by the pharmaceutical industry. In the open label
study almost 3,000 subjects were treated with an extended
release mixed amfetamine salt (MAS) preparation over a
7 week period [71]. QoL as measured by the total score on
the parent rated PedsQL improved significantly from
baseline to endpoint. Wigal et al. [92] measured QoL using
the PedsQL during a randomized controlled double-blind
laboratory school study comparing this same extended
release mixed amfetamine salt preparation with atomoxe-
tine. Both treatments resulted in statistically significant
improvements in QoL from baseline to endpoint. The mean
difference from baseline on the PedsQL for MAS was 7.9
unit points and for atomoxetine was 7.1 unit points
(p \ 0.0001). There were no differences between the two
medications with respect to the total ADHD scores or the
ADHD symptom subscale scores. The two treatments did,
however, differ with respect to QoL was seen on the school
functioning subscale on which there was a greater
improvement in the amfetamine treated group (34%)
compared to the atomoxetine treated group (25%). The
least square mean difference of 6.94 unit points (95% CI,
-2.45, 11.42) indicated a positive effect of MAS over
atomoxetine, a difference that was statistically significant
[92].
Atomoxetine
This has been the most extensively studied ADHD medi-
cation from the perspective of QoL. Again all studies have
been sponsored by the pharmaceutical industry. Combining
data from three randomized double-blind controlled trials,
Perwien et al. [57] documented that improvements on
atomoxetine over and above those seen on placebo in the
psychosocial summary score (d = 0.55, p = 0.0001), but
not the physical summary score (d = -0.11, p [ 0.05).
Significant improvements were also found for the behav-
iour, family activities, parental impact time, role emotional/
behavioural and mental health scale scores (d = 0.26-
0.55, p \ 0.05) of the parent rated CHQ-PF-50. Benefits
were demonstrated after 7–8 weeks treatment. Lower
baseline QoL scores, no prior stimulant use and absence of
ODD were associated with improved QoL at endpoint. No
difference was found between once or twice daily dosing
schedules and there was no evidence to support a dose
response curve for the doses tested. Response rates, defined
as having a score within 1.5 standard deviations of
the normative mean, were lower for QoL than they were
for ADHD symptoms. A subsequent independent meta-
regression analysis of nine randomized placebo-controlled
trials with atomoxetine confirmed the improvement of QoL
on the psychosocial summary score of the CHQ-PF50 in
atomoxetine treated children and adolescents compared to
placebo (Standardised Mean Difference 0.47, 95% CI 0.25–
0.69) [16]. Both children with ADHD with and without
ODD showed significant changes in the psychosocial
summary score and on most subscales of the CHQ-PF-50
after 8 weeks of treatment with atomoxetine [52]. These
findings were endorsed by a meta-analysis of the results of
this and two other studies [13]. However, although the CHQ
and symptom-based findings were generally similar, they
varied to some extent as a function of group and dose, with
some subscales separating from placebo in the 1.8-mg/kg/
day dose group and not the 1.2-mg/kg/day group. This
underscores the importance of looking beyond symptomatic
control when evaluating treatments for ADHD.
Brown et al. [15] found only a trend toward a better
response to active treatment with atomoxetine than to
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placebo after a 7 week double-blind trial in children with
ADHD, while significant improvements were found on both
parent and teacher symptom ratings. The effect size relative
to placebo was small (d = 0.32). With response defined as a
total T-score below 60 on the CHQ, significantly more
children responded to active medication (43.8%) than to
placebo (22.2%). In a UK study, children were randomized
to open label atomoxetine or standard current treatment [60].
Over a 10-week period, overall QoL in children with ADHD
improved significantly, as measured with the CHIP-CE total
score. A differential effect was found between the study
treatments, in favour of atomoxetine over standard ‘‘treat-
ment as usual’’ (mainly methylphenidate). In the atomoxe-
tine group children’s mean total CHIP-CE score increased
from 23.2 to 38.4, which is still more than one standard
deviation below the norm of 50. After 10 weeks all five
parent-reported sub-domains of the CHIP-CE (satisfaction,
comfort, risk avoidance, resilience and achievement) were
improved. Much less improvement was seen on the patient-
reported Harter Self Perception Profile, with only one scale
(social acceptance domain) showing significant change.
Possible reasons for the larger improvement for atomoxetine
than methylphenidate suggested by the authors are, a more
persistent effect of atomoxetine, with less fluctuations and a
possible additional effect on anxiety or tic symptoms [60]. It
is also possible that whilst treatment with atomoxetine was
optimized during the trial the treatments used in the ‘‘treat-
ment as usual’’ was not.
There is little data on longer term treatment effects on
QoL. Perwien et al. [58] report on the changes in the CHQ-
PF-50 over a 10-weeks period and over 24 months open
label treatment with atomoxetine. Significant effects were
found for the psychosocial scales in the acute treatment
phase and these were preserved over the long term, how-
ever, no additional improvement in QoL was observed
between 10 weeks and 24 months.
Other medications
Using an unlicensed novel inhibitor of noradrenaline and
dopamine reuptake (GW320659), a statistically significant
improvement was observed in the psychosocial summary
score of the shorter CHQ-PF-28 by DeVeaugh-Geiss et al.
[20].
In summary, there is emerging evidence that QoL
improves following effective treatment. This evidence is,
however, almost entirely limited to pharmacological
treatments and to atomoxetine in particular and almost
entirely based on parent report. Several issues still require
to be addressed including; the overlap and interactions
between improvements QoL and reduction in symptoms
and an assessment of the clinical relevance of various
degrees of change.
Discussion
QoL is being increasingly recognized as an important
component of a comprehensive assessment of the impact
on children and young people of health problems, in gen-
eral, and ADHD, in particular. However, the QoL concept
remains problematic in a number of ways, with multiple
competing definitions and measurement approaches [18].
These issues complicate the interpretation of the existing
data relating to QoL in ADHD. Notwithstanding these
limitations, in the current review we have brought together
the existing published data on QoL in ADHD. This allows
us to assess the implications of these findings, reflect on
issues of interpretation and identify areas for future study.
The current published evidence indicates that QoL is
impaired in children with ADHD according to parental
report. Across different measures of QoL parents consis-
tently rate the QoL of their children with ADHD as
between 1.5 and 2 SD below the appropriate population
norms. Furthermore the evidence suggests that QoL
impairment increases as the severity of disorder increases,
and/or where it is complicated by the presence of comor-
bidity or psychosocial stressors. The most robust effects are
found on the psycho-social and achievement-related mea-
surement scales and those that assess impact on family life.
Both inattentive and hyperactive/impulsive ADHD symp-
toms appear to be equally related to this reduction in QoL.
Furthermore, there is evidence to support treatment effects
on QoL that to some extent mirror their effects on ADHD
symptoms, although with smaller effect sizes. While there
is some evidence for child reported reductions in QoL this
is less consistent than for parent ratings. There is also fairly
consistent evidence that parents and children assess QoL
differently, as evidenced by the, modest, correlations
between parent and child reports, and that parents tend to
rate their children with ADHD as having lower QoL than
do the children themselves. While these may in part be
related to the measures used (neither of the studies that
used the child rated CHQ reported differences between
ADHD and healthy children but all four of those that used
other scales did) there are several other factors that could
account for these findings. Inconsistencies between child
and parent ratings of QoL may also reflect age, or sample
differences as well as error or true differences. In contrast
to children with other psychiatric conditions (e.g., depres-
sion), children with ADHD may have an over-optimistic
view of their situation. A similar effect has been demon-
strated in many studies of self-esteem and self-concept in
children with ADHD where it has been hypothesized as
being the result of a positive illusory bias [35, 55]. Children
with ADHD are hypothesized to overestimate their own
abilities and performance in order to protect a positive self-
image [54]. Experimental studies have supported aspects of
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this proposed mechanism [35, 54] and it may be important
for similar studies to be designed with respect to child
reports of QoL in ADHD. Klassen et al. [39] have sug-
gested several other possible reasons for the discrepant
findings between child and parent reports of QoL; children
may want to conceal their problems; they may ignore them
in an attempt to cope with them; they may undergo a
process of adaptation to disorder leading to a shift in their
internal standards leading to changes in evaluation; they
may be making systematic mistakes in rushing through the
questionnaires because of their impulsive cognitive style.
The finding of larger discrepancies between self- and par-
ent-ratings in children with comorbid ODD/CD and those
with additional psychosocial stressors may support the first
two hypotheses. This pattern of discrepancy between
informants also raises a fundamental conceptual issue
given that, in its purest sense, QoL has a strong element of
self evaluation. If this view was taken to its logical con-
clusion the child’s view would trump that of the parents.
However, at this stage we suggest that a pragmatic
approach should involve attempts to develop methods that
allow the combining of both proxy and child ratings in
order to provide a more comprehensive and integrated
assessment [83]. There will, however, need to be more
work exploring the psychometric properties of child-report
instruments both in general and in ADHD specifically.
Future research, including head to head comparisons of
parent and child ratings and experimental studies, should
also address the differing ways by which children and
parents construct the experience and impact of ADHD on
the child’s QoL. Developmentally sensitive designs that
can describe the impact of ADHD on QoL at different ages
and the progression of QoL over time would also be very
welcome. Large datasets, particularly those derived from
community samples, should also be interrogated using data
reduction techniques such as factor analysis to identify
latent variables. Of particular interest will be studies that
have used more than one measure of QoL whereby com-
monalities between different measures can be identified
and possibly translated into new instruments with improved
validity and reliability.
Relatively few child studies have compared QoL in
ADHD either with QoL in other psychiatric disorders or
with chronic physical disorders. Those studies that have
been conducted have started to suggest that different
disorders may result in different QoL profiles, however,
more and larger studies will improve our understanding
considerably.
More work is also required to improve our understand-
ing of both the differences and interrelationships between
the different levels of analysis that comprise a child’s
overall functioning (e.g. ADHD symptoms, associated
functional impairment and QoL) as these concepts are
currently not well delineated either theoretically or on a
practical level within the different measurement scales.
Different questionnaires contain different mixes of items
which tap into all three levels. This means that there is
inevitably item-overlap between symptoms rating scales
and QoL measures and it then becomes difficult to tease out
any independent effects that the disorder or its treatment
may be having on symptoms on the one hand and QoL on
the other. This in turn begs the question as to whether an
apparent treatment related change as measured by current
QoL instruments actually adds anything to our under-
standing of treatment effects. Whilst we believe that
measures of QoL can add considerable colour to the
measurement of treatment outcome future research needs
to address the contribution of these different elements in
characterizing ADHD and its relationship to QoL. A major
question to be addressed here would be; does the concept
of QoL add any value to our understanding of ADHD over
and above the concepts of symptoms and more specific
functional impairment? One study [74], explicitly studied
aspects of this overlap and reported that the removal of
potentially overlapping (symptom) items made little dif-
ference to the relationships between mental illness and
QoL that they had previously established. There is the
potential for similar analyses to be conducted with existing
datasets and this may help to provide a more definitive
answer to this question. This may suggest ways that the
existing measures of QoL could be refined for use with
ADHD populations or scored differently when used in this
group. This may also result in a clearer delineation of the
key characteristics that lay at the core of QoL that are
independent of both symptoms and general functional
impairment.
Even within the currently limited research into QoL in
children with ADHD there is a lack of consistency in terms
of the instruments used to measure QoL. These different
instruments have been organized into substantially differ-
ent sub-scale structures and content [18] which has made it
very hard to compare QoL across studies and disorders.
These differences between the instruments and between
researchers regarding their preferred measure are likely to
reflect different opinions regarding the best conceptuali-
zation of QoL and emphasize the lack of an agreed core
QoL paradigm. Sufficient data has not yet been published
to perform a meaningful meta-analysis of studies and
instruments from which steps could be taken towards the
development of a core set of items that could in turn lead to
the development of a common instrument. Of course as is
frequently the case in psychological research the authors of
the current measures of QoL will often have substantial
academic and/or financial investment in their own tool and
may therefore also be reluctant to engage in a process by
which their own measure may be used less frequently in
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future studies. While it is not possible at this stage to
recommend one measures as being superior to the others it
would be beneficial for studies to be conducted that com-
pared different measures in head to head designs in order
that their performance in different groups and different
contexts can be described. Studies in children and young
people with ADHD that combine questionnaire and inter-
view methods would also be helpful to support the validity
of these measures in this group.
Most studies to date have relied on clinic-referred
samples, and thus have the potential for referral and
Berkson’s bias [9]. This has led to a reduced range in
outcomes and associated limitations on the power of sta-
tistical tests. Further studies are required, to anchor these
effects within the wider population.
Most studies have used parental reports both for symp-
tom severity and QoL. This introduces the problem of
shared-rater variance and may induce at least two possible
sources of bias. This could result in a spurious association
between ADHD symptoms and QoL and leaves both
measures open to undue influence by parent characteristics:
other than the very general data from the ADORE study
mentioned above [68], we are unaware of any studies that
have investigated the effect of parental mental health on
measures of their child’s QoL. Future studies should, as a
matter of course, take independent ratings of QoL and
symptoms. The choice of who should act as the second
informant itself raises a number of issues. In the broader
field of ADHD, teachers’ ratings are often used to address
this problem. However, the low correlations found between
ratings of QoL by the child or parent and teacher-reported
symptoms may be accounted for by the fact that teachers
are interested in and observe different maladaptive and
adaptive behaviours in the classroom than parents do at
home, or that they often only see the children when they
are medicated. On the other hand, it is also possible that
parents may have exaggerated both symptoms and impact
on well-being.
Finally, treatment studies have, to date, been extremely
limited in their scope. Studies have focused almost exclu-
sively on one treatment modality (pharmacological) and
one molecule (atomoxetine). Stimulants (amfetamines,
methylphenidate) are also recommended for the treatment
of ADHD [4]. In view of the many measurement issues
described above we are not yet at a stage whereby QoL
measures can be considered as serious contenders as pri-
mary outcome measures in major clinical trials although
this may change in the future. One particular psychometric
issue that requires clarification in this respect is clarifica-
tion of what constitutes a clinically meaning change for
these measures. We do, however, strongly recommend
that those designing and conducting future clinical trials,
both pharmacological and psychosocial, should include
measures of QoL as secondary outcome measures.
Although we are aware of several ongoing RCTs of stim-
ulant medication that are using QoL measures at present no
systematic published data from RCTs on the impact of
methylphenidate on QoL in ADHD, only one RCT of
amfetamines and none with psychosocial treatment, this
needs to be addressed urgently. It should also be noted that
the total number of individual children that have had their
QoL measured as a part of the atomoxetine development
program is less than it may initially appear to the casual
reader. Several of the meta analyses have included data
from the same trials and all of the children in the long term
open label follow-up study described by Perwin et al. [58]
were enrolled into the long term study following their
having completed participation in an RCT and are therefore
likely to be included in at least one other publication. The
lack of systematic studies of psychological therapies either
on their own or in multimodal combinations with medi-
cation is a further omission in our understanding of the
impact of treatment on QoL.
Studies have, on the whole, had relatively short follow-
up periods and it may be the case that some aspects of QoL
will take more time for change and would therefore not be
seen in these short-term clinical trials. However, Perwien
et al.’s longer term study [58] failed to show any additional
improvement in QoL after the acute treatment period.
There has been no systematic analysis of the extent to
which changes in QoL are mediated by symptom changes,
changes in functional impairment or other factors. This task
is complicated enormously by the fact that the concept of
QoL appears to be somewhat confounded in current scales
with ADHD symptoms and functional impairment.
Although it is likely that QoL, in relation to medication
response, will probably be influenced by a mixture of
positive treatment responses and side effects the role of
adverse events, in determining QoL following treatment,
has not yet been reported in any of the published studies.
Most studies have either had strict inclusion and
exclusion criteria that have not allowed the recruitment of
those with comorbid disorders or have failed to control for
comorbid disorders such as ODD, anxiety and depression,
either at baseline or when assessing the responsiveness of
QoL to treatment, even though it is recognized that several
subscales of the QoL measures contain items on behaviour
problems, depressive symptoms and anxiety. At the same
time, it seems clear that some of the QoL effects demon-
strated in ADHD are clearly distinct from ADHD symp-
toms, e.g. peer and family relation impact.
The ADORE study [61] collected naturalistic observa-
tional data on ADHD symptoms, impairment, comorbidity
and QoL over a 2 years period on a large group of children
and young people with ADHD who were receiving a
wide range of pharmacological and non-pharmacological
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treatments. Data from the longitudinal portion of this study
has been submitted for publication and will help to address
many of these issues. However, it is also essential that
further well designed clinical trials which utilise both child
and parent proxy completed QoL measures are conducted
and in particular head-to-head studies of different treatment
packages with a broad range of outcomes over extended
periods of time, with multiple testing points are required.
These studies should be designed in such a way to allow
the exploration of the natural history of changes in QoL
following treatment as well as the mediating effects of
symptom reductions and other factors on longer term
changes in well-being.
In addition to acting as an outcome measure QoL
measures could be helpful within the clinical setting as an
indicator of clinical need and assist the clinician in iden-
tifying areas of life that are particularly difficult for a child
in order that appropriate support can be engaged. ADHD
impacts on many aspects of life and although clinicians
now have much more information regarding the best ways
to reduce ADHD symptoms it is also important for us to
always be alert to the associated difficulties faced by these
children and to consider how best we can improve their
lives.
In summary, published studies to a degree support an
impact of ADHD on QoL, which is at least as great as seen
for many physical disorders. These effects are greatest, and
most consistent, with parent ratings than child-self ratings.
Future research needs to distinguish QoL effects from those
related only to symptoms and functional impairment; study
the differences between child and parent perceptions of
ADHD and its impact; identify common elements across
the multiple measures currently in use; use population as
well clinical samples; include independent ratings of QoL
and ADHD symptoms; study the effects of a broader range
of treatments in a way that allows the assessment of
mediating and moderating factors.
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